Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 184-189 , July 2007

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

  • Henry K. Tsai, MD
    • ,
  • Peter M. Mauch, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Peter M. Mauch, MD, Department of Radiation Oncology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115.

References 

  1. Jackson HJ, Parker FJ. Hodgkin’s disease (II. Pathology). N Engl J Med. 1944;231:35–44
  2. Wright CJ. The “benign” form of Hodgkin’s disease (Hodgkin’s paragranuloma). J Pathol Bacteriol. 1960;80:157–171
  3. Smetana HF, Cohen BM. Mortality in relation to histologic type in Hodgkin’s disease. Blood. 1956;11:211–224
  4. Hanson TA. Histological classification and survival in Hodgkin’s disease: A study of 251 cases with special reference to nodular sclerosing Hodgkin’s disease. Cancer. 1964;17:1595–1603
  5. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin’s disease. Cancer Res. 1966;26:1063–1083
  6. Harris NL, Jaffe ES, Stein H. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  7. Diehl V, Sextro M, Franklin J. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17:776–783
  8. Miettinen M, Franssila KO, Saxen E. Hodgkin’s disease, lymphocytic predominance nodular (Increased risk for subsequent non-Hodgkin’s lymphomas). Cancer. 1983;51:2293–2300
  9. Regula DP, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease. N Engl J Med. 1988;318:214–219
  10. Mauch PM, Kalish LA, Kadin M. Patterns of presentation of Hodgkin disease (Implications for etiology and pathogenesis). Cancer. 1993;71:2062–2071
  11. Borg-Grech A, Radford JA, Crowther D. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1989;7:1303–1309
  12. Bodis S, Kraus MD, Pinkus G. Clinical presentation and outcome in lymphocyte-predominant Hodgkin’s disease. J Clin Oncol. 1997;15:3060–3066
  13. Leibenhaut MH, Hoppe RT, Efron B. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin’s disease. J Clin Oncol. 1989;7:81–91
  14. Ha CS, Kavadi V, Dimopoulos MA. Hodgkin’s disease with lymphocyte predominance: Long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys. 1999;43:329–334
  15. Hutchings M, Loft A, Hansen M. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24:146–150
  16. Hansmann ML, Zwingers T, Boske A. Clinical features of nodular paragranuloma (Hodgkin’s disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol. 1984;108:321–330
  17. Wirth A, Yuen K, Barton M. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221–1229
  18. Nogova L, Reineke T, Eich HT. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683–1687
  19. Wilder RB, Schlembach PJ, Jones D. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94:1731–1738
  20. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13(suppl 1):79–83
  21. Rehwald U, Schulz H, Reiser M. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101:420–424
  22. Ekstrand BC, Lucas JB, Horwitz SM. Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood. 2003;101:4285–4289
  23. Girinsky T, Guillot-Vals D, Koscielny S. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148–155
  24. Johannsson J, Specht L, Mejer J. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys. 2002;54:1466–1470
  25. Haas RL, Poortmans P, de Jong D. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474–2480
  26. Haas RL, Poortmans P, de Jong D. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer. 2005;41:1724–1730
  27. Pappa VI, Norton AJ, Gupta RK. Nodular type of lymphocyte predominant Hodgkin’s disease (A clinical study of 50 cases). Ann Oncol. 1995;6:559–565
  28. Crennan E, D’Costa I, Liew KH. Lymphocyte predominant Hodgkin’s disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys. 1995;31:333–337
  29. Orlandi E, Lazzarino M, Brusamolino E. Nodular lymphocyte predominance Hodgkin’s disease: Long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997;26:359–368
  30. Feugier P, Labouyrie E, Djeridane M. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood. 2004;104:2675–2681
  31. Schlembach PJ, Wilder RB, Jones D. Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J. 2002;8:377–383
  32. Trudel MA, Krikorian JG, Neiman RS. Lymphocyte predominance Hodgkin’s disease (A clinicopathologic reassessment). Cancer. 1987;59:99–106
  33. Tefferi A, Zellers RA, Banks PM. Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin’s disease. J Clin Oncol. 1990;8:1959–1965

PII: S1053-4296(07)00015-X

doi: 10.1016/j.semradonc.2007.02.004

Seminars in Radiation Oncology
Volume 17, Issue 3 , Pages 184-189 , July 2007

Article Tools